Tarsus Pharmaceuticals Inc
NASDAQ:TARS
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
Price:
74.77
USD
-0.17%
Market Cap:
$3.2B
Income Statement
Earnings Waterfall
Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
Income Statement
Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
Currency: USD
| Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
3
|
3
|
3
|
3
|
5
|
6
|
8
|
9
|
9
|
9
|
0
|
|
| Revenue |
55
N/A
|
57
+2%
|
57
+1%
|
24
-58%
|
17
-28%
|
16
-7%
|
26
+60%
|
28
+8%
|
13
-55%
|
14
+15%
|
17
+21%
|
43
+144%
|
83
+96%
|
130
+55%
|
183
+41%
|
234
+28%
|
296
+26%
|
366
+24%
|
451
+23%
|
|
| Gross Profit | ||||||||||||||||||||
| Cost of Revenue |
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(1)
|
(2)
|
(3)
|
(6)
|
(9)
|
(13)
|
(16)
|
(20)
|
(25)
|
(31)
|
|
| Gross Profit |
53
N/A
|
55
+2%
|
55
+1%
|
23
-58%
|
17
-28%
|
16
-7%
|
25
+59%
|
27
+8%
|
12
-55%
|
14
+12%
|
16
+17%
|
39
+148%
|
77
+96%
|
121
+56%
|
170
+41%
|
217
+28%
|
276
+27%
|
341
+24%
|
421
+23%
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(57)
|
(64)
|
(67)
|
(66)
|
(72)
|
(78)
|
(88)
|
(95)
|
(108)
|
(127)
|
(159)
|
(195)
|
(233)
|
(261)
|
(291)
|
(328)
|
(374)
|
(429)
|
(492)
|
|
| Selling, General & Administrative |
(18)
|
(23)
|
(25)
|
(28)
|
(32)
|
(37)
|
(45)
|
(52)
|
(62)
|
(80)
|
(109)
|
(145)
|
(184)
|
(211)
|
(237)
|
(271)
|
(315)
|
(366)
|
(427)
|
|
| Research & Development |
(39)
|
(41)
|
(42)
|
(38)
|
(40)
|
(41)
|
(43)
|
(43)
|
(46)
|
(47)
|
(50)
|
(50)
|
(50)
|
(50)
|
(53)
|
(56)
|
(59)
|
(63)
|
(64)
|
|
| Operating Income |
(4)
N/A
|
(9)
-153%
|
(12)
-32%
|
(42)
-249%
|
(55)
-29%
|
(62)
-13%
|
(63)
-1%
|
(68)
-9%
|
(96)
-41%
|
(114)
-19%
|
(143)
-26%
|
(156)
-9%
|
(156)
0%
|
(141)
+10%
|
(121)
+14%
|
(111)
+8%
|
(98)
+12%
|
(87)
+11%
|
(71)
+19%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
1
|
3
|
5
|
6
|
8
|
7
|
8
|
8
|
6
|
6
|
6
|
6
|
7
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(2)
|
(2)
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
1
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(5)
N/A
|
(10)
-130%
|
(14)
-32%
|
(45)
-225%
|
(57)
-27%
|
(63)
-11%
|
(62)
+2%
|
(65)
-5%
|
(91)
-39%
|
(108)
-18%
|
(136)
-26%
|
(148)
-9%
|
(150)
-1%
|
(134)
+10%
|
(116)
+14%
|
(105)
+9%
|
(92)
+12%
|
(81)
+12%
|
(64)
+21%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
(0)
|
0
|
(0)
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
|
| Income from Continuing Operations |
(5)
|
(10)
|
(14)
|
(44)
|
(57)
|
(63)
|
(62)
|
(65)
|
(91)
|
(108)
|
(136)
|
(148)
|
(150)
|
(134)
|
(116)
|
(105)
|
(92)
|
(81)
|
(66)
|
|
| Net Income (Common) |
(5)
N/A
|
(10)
-114%
|
(14)
-32%
|
(44)
-221%
|
(57)
-27%
|
(63)
-12%
|
(62)
+2%
|
(65)
-5%
|
(91)
-39%
|
(108)
-18%
|
(136)
-26%
|
(148)
-9%
|
(150)
-1%
|
(134)
+10%
|
(116)
+14%
|
(105)
+9%
|
(92)
+12%
|
(81)
+12%
|
(66)
+18%
|
|
| EPS (Diluted) |
-0.23
N/A
|
-0.5
-117%
|
-0.67
-34%
|
-2.15
-221%
|
-2.32
-8%
|
-2.37
-2%
|
-2.52
-6%
|
-2.44
+3%
|
-3.4
-39%
|
-3.51
-3%
|
-4.62
-32%
|
-4.19
+9%
|
-3.96
+5%
|
-3.5
+12%
|
-3.07
+12%
|
-2.66
+13%
|
-2.17
+18%
|
-1.9
+12%
|
-1.59
+16%
|
|
Switch to:
Switch to:
See Also
Discover More
